Progress in Gene Therapy for Hereditary Tyrosinemia Type 1

Area of Science:

• Biochemistry
• Genetics
• Metabolic Disorders

Background:

• Hereditary Tyrosinemia Type-1 (HT1) is a severe inherited metabolic disorder.
• Current treatments like NTBC manage acute symptoms but have limitations, including neurocognitive effects and dietary restrictions.
• Gene therapy (GT) presents a potential one-dose curative strategy for HT1.

Purpose of the Study:

• To review preclinical HT1 gene therapy data and clinical data from other liver-directed GT trials.
• To identify the most promising vector-payload combination for a one-dose HT1 cure.
• To guide the translation of preclinical findings into clinical applications.

Main Methods:

• Review of preclinical data for Hereditary Tyrosinemia Type-1 gene therapy.
• Analysis of clinical trial data for liver-directed gene therapy in other diseases.
• Comparative assessment of different vector-nucleotide payload combinations.

Main Results:

• Lentiviral-based approaches are strongly supported for clinical progression in HT1 gene therapy.
• Several vector-payload combinations show potential for a curative, single-dose HT1 treatment.
• Knowledge gaps exist regarding the optimal vector-payload for successful clinical translation.

Conclusions:

• Gene therapy holds significant promise as a one-dose cure for HT1, moving beyond symptom management.
• Lentiviral vectors are a leading candidate for clinical trials, but further investigation into alternative vector-payload combinations is warranted.
• Additional research is crucial to determine the most scientifically and commercially viable gene therapy approach for HT1.